Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016

Alkermes plc
Posted on: 19 Sep 16

Alkermes plc (NASDAQ: ALKS) announced today that it will webcast its Analyst and Investor Event presentation on Monday, September 26, 2016. The webcast will begin at 2:00 p.m. EDT (7:00 p.m. BST). At the event, members of Alkermes’ senior management will provide an overview of medical, commercial, policy and market perspectives for VIVITROL® (naltrexone for extended-release injectable suspension).

A live webcast of the event will be available on the Investors section of the company’s website at To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start. This webcast will be archived on the Investors section of the company’s website at for one month following the presentation.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.